Kiniksa Pharmaceuticals (KNSA) Revenue & Revenue Breakdown
Kiniksa Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$423.24M
Latest Revenue (Q)
$112.21M
Main Segment (Y)
Product
Kiniksa Pharmaceuticals Revenue by Period
Kiniksa Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $423.24M | 56.60% |
2023-12-31 | $270.26M | 22.74% |
2022-12-31 | $220.18M | 471.24% |
2021-12-31 | $38.54M | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | - |
Kiniksa Pharmaceuticals generated $423.24M in revenue during NA 2024, up 56.60% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Kiniksa Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $112.21M | 3.30% |
2024-06-30 | $108.63M | 36.03% |
2024-03-31 | $79.86M | -4.24% |
2023-12-31 | $83.39M | 24.38% |
2023-09-30 | $67.05M | -6.19% |
2023-06-30 | $71.47M | 47.84% |
2023-03-31 | $48.34M | -21.88% |
2022-12-31 | $61.88M | -37.58% |
2022-09-30 | $99.14M | 267.55% |
2022-06-30 | $26.97M | -16.21% |
2022-03-31 | $32.19M | 71.72% |
2021-12-31 | $18.75M | 54.98% |
2021-09-30 | $12.10M | 57.00% |
2021-06-30 | $7.70M | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | - |
Kiniksa Pharmaceuticals generated $112.21M in revenue during Q3 2024, up 3.30% compared to the previous quarter, and up 157.00% compared to the same period a year ago.
Kiniksa Pharmaceuticals Revenue Breakdown
Kiniksa Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 24 | Dec 23 | Dec 22 |
---|---|---|---|
Product | $417.03M | $233.18M | $122.52M |
Collaboration | $6.21M | $37.08M | $97.66M |
Latest
Kiniksa Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (98.53%), and Collaboration (1.47%).
Quarterly Revenue by Product
Product/Service | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|---|---|---|---|---|---|---|
Product | $201.42M | $112.21M | $103.39M | $136.02M | $54.49M | $42.66M | $39.94M | $33.42M | $26.97M | $22.19M |
Collaboration | - | $6.21M | $5.24M | $14.42M | $16.98M | $5.69M | $21.95M | - | - | - |
Latest
Kiniksa Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).
Kiniksa Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
KNSA | Kiniksa Pharmaceuticals | $423.24M | $112.21M |
CHRS | Coherus BioSciences | $266.96M | $70.77M |
DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
GOSS | Gossamer Bio | $114.70M | $9.48M |
ACLX | Arcellx | $107.94M | $26.03M |
PHAT | Phathom Pharmaceuticals | $55.25M | $16.35M |
KURA | Kura Oncology | $53.88M | - |
SPRO | Spero Therapeutics | $47.98M | $13.47M |
KRON | Kronos Bio | $9.85M | $2.37M |
BOLT | Bolt Biotherapeutics | $7.69M | $1.14M |
LYRA | Lyra Therapeutics | $1.53M | $195.00K |
CGEM | Cullinan Oncology | - | - |
GPCR | Structure Therapeutics | - | - |
VTYX | Ventyx Biosciences | - | - |
NUVL | Nuvalent | - | - |
COGT | Cogent Biosciences | - | - |
REPL | Replimune Group | - | - |
NVCT | Nuvectis Pharma | - | - |
LRMR | Larimar Therapeutics | - | - |